medigraphic.com
ISSN 0035-0052 (Impreso)

2009, Número 3

<< Anterior Siguiente >>

Rev Mex Pediatr 2009; 76 (3)


Tratamiento con sildenafil en una niña con hipertensión pulmonar: El caso de una preescolar

González FAE, Aguilar AM, Rodríguez MR

Idioma: Español
Referencias bibliográficas: 37
Paginas: 124-127
Archivo PDF: 176.41 Kb.


RESUMEN

El propósito de este reporte es describir la experiencia clínica y el seguimiento relacionado con la respuesta al tratamiento de una niña con hipertensión arterial pulmonar (HTP); al nacer tuvo varias anomalías congénitas del corazón (comunicación interauricular y persistencia del conducto arterioso) y hernia diafragmática de Bochdalek. A los dos días de nacida fue llevada a cirugía para corrección de la hernia y a los seis meses de edad se le corrigieron las malformaciones cardiacas. A los 22 meses de edad se le hizo el diagnóstico de hipertensión arterial pulmonar (HTP) sin respuesta al tratamiento convencional, por lo que se le inició tratamiento con sildenafil a 2 mg/kg/dosis cada seis horas, obteniendo una buena respuesta. Un año después de iniciado el tratamiento ha mostrado una progresiva mejoría clínica y ecocardiográfica. A los tres años se halla asintomática.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Rashid A, Ivy D. Severe pediatric pulmonary hypertension: New Managements Strategies. Arch Dis Child 2005; 90: 92-98.

  2. Kinsella JP, Truog WE, Walsh WF, Goldberg RN, Bancalari E, Reese H et al. Randomized, multicenter trial of inhaled nitric oxide and high frequency oscillatory ventilation in severe

  3. persistent pulmonary hypertension of the newborn (PPHN). Pediatric Research 1996; 39(4) Supplement 2: 222.

  4. Rabinovitch M. Pathophysiology of pulmonary hypertension. In: Moss and Adams. Heart disease in infants, children and adolescents. Seventh Edition. Lippincott, Williams & Wilkins, 2008: 1322.

  5. Doyle RL. Early diagnosis and treatment of pulmonary arterial hypertension. Medscape Pulmonary Medicine 2005; 9(1).

  6. Yung D, Widlitz AC, Rosenzweig EB, Kerstein D, Maislin G, Barst RJ. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 2004; 110: 660-5.

  7. Ivy DD, Griebel JL, Kinsella JP, Abman SH. Acute hemodynamic effects of pulsed delivery of low flow nasal nitric oxide in children with pulmonary hypertension. J Pediatr 1998; 133(3): 453-6.

  8. Hill N. Therapeutic options for the treatment of pulmonary hypertension. Medscape Pulmonary Medicine 2005: 9(2).

  9. Maiya S, Hislop AA, Flynn Y, Haworth SG. Response to bosentan in children with pulmonary hypertension. Heart 2006; 92: 664-70.

  10. Khun K, Wickersham N, Robbins I, Byme D. Acute effects of sildenafil in patients with primary pulmonary hypertension receiving epoprostenol. Exp Lungs Res 2004; 30(2): 135-45.

  11. Fernández N, Rodríguez A, Jerez J, Parrondo SM, Martínez L. Sildenafil oral como tratamiento de un neonato con hipertensión pulmonar persistente. Ann Pediatr 2004; 61(6): 567-8.

  12. Karatza AA, Busch A, Magee AG. Reversal of shunting in pulmonary hypertension after treatment with oral sildenafil. Cardiol Young 2002; 12(6): 561-2.

  13. Lepore JL, Maroo A, Pereira NL, Ginns LC, Dec GW, Zapol WM et al. Effect of sildenafil on the acute pulmonary vasodilatator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol 2002; 90(6): 677-80.

  14. Karatza AA, Busch A, Magee AG. Safety and efficacy of sildenafil therapy in children with pulmonary hypertension. Int J Cardiol 2005; 100(2): 267-73.

  15. Yeo TC, Dujardin KS, Tei C, Mahoney DW, McGoon MD, Seward JB. Value of a Doppler derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol 1998; 81(9): 1157-61.

  16. Gohfrani HA, Wiedermann R, Rose F, Schermuly RT, Olschewski H, Weissmann N et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: A randomized controlled trial. Lancet 2002; 360(9337): 895-900.

  17. Rosenzwein EB, Barst RI. Clinical managements of patients with pulmonary hypertension. In: Moss and Adams. Heart disease in infants, children and adolescent. 7th ed. Philadelphia: Lippincott Williams & Wilkins, 2008: 1355-68.

  18. Galie N, Ghofrani H, Torbicki A, Barst RJ, Rubin LJ, Badesch D et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353(20): 2148-57.

  19. Michelakis E, Tymchack W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: Comparison with inhaled nitric oxide. Circulation 2002; 105: 2398-403.

  20. Rashid A, Ivy D. Severe pediatric pulmonary hypertension: New Managements Strategies. Arch Dis Child 2005; 90: 92-98.

  21. Kinsella JP, Truog WE, Walsh WF, Goldberg RN, Bancalari E, Reese H et al. Randomized, multicenter trial of inhaled nitric oxide and high frequency oscillatory ventilation in severe persistent pulmonary hypertension of the newborn (PPHN). Pediatric Research 1996; 39(4) Supplement 2: 222.

  22. Rabinovitch M. Pathophysiology of pulmonary hypertension. In: Moss and Adams. Heart disease in infants, children and adolescents. Seventh Edition. Lippincott, Williams & Wilkins, 2008: 1322.

  23. Doyle RL. Early diagnosis and treatment of pulmonary arterial hypertension. Medscape Pulmonary Medicine 2005; 9(1).

  24. Yung D, Widlitz AC, Rosenzweig EB, Kerstein D, Maislin G, Barst RJ. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 2004; 110: 660-5.

  25. Ivy DD, Griebel JL, Kinsella JP, Abman SH. Acute hemodynamic effects of pulsed delivery of low flow nasal nitric oxide in children with pulmonary hypertension. J Pediatr 1998; 133(3): 453-6.

  26. Hill N. Therapeutic options for the treatment of pulmonary hypertension. Medscape Pulmonary Medicine 2005: 9(2).

  27. Maiya S, Hislop AA, Flynn Y, Haworth SG. Response to bosentan in children with pulmonary hypertension. Heart 2006; 92: 664-70.

  28. Khun K, Wickersham N, Robbins I, Byme D. Acute effects of sildenafil in patients with primary pulmonary hypertension receiving epoprostenol. Exp Lungs Res 2004; 30(2): 135-45.

  29. Fernández N, Rodríguez A, Jerez J, Parrondo SM, Martínez L. Sildenafil oral como tratamiento de un neonato con hipertensión pulmonar persistente. Ann Pediatr 2004; 61(6): 567-8.

  30. Karatza AA, Busch A, Magee AG. Reversal of shunting in pulmonary hypertension after treatment with oral sildenafil. Cardiol Young 2002; 12(6): 561-2.

  31. Lepore JL, Maroo A, Pereira NL, Ginns LC, Dec GW, Zapol WM et al. Effect of sildenafil on the acute pulmonary vasodilatator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol 2002; 90(6): 677-80.

  32. Karatza AA, Busch A, Magee AG. Safety and efficacy of sildenafil therapy in children with pulmonary hypertension. Int J Cardiol 2005; 100(2): 267-73.

  33. Yeo TC, Dujardin KS, Tei C, Mahoney DW, McGoon MD, Seward JB. Value of a Doppler derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol 1998; 81(9): 1157-61.

  34. Gohfrani HA, Wiedermann R, Rose F, Schermuly RT, Olschewski H, Weissmann N et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: A randomized controlled trial. Lancet 2002; 360(9337): 895-900.

  35. Rosenzwein EB, Barst RI. Clinical managements of patients with pulmonary hypertension. In: Moss and Adams. Heart disease in infants, children and adolescent. 7th ed. Philadelphia: Lippincott Williams & Wilkins, 2008: 1355-68.

  36. Galie N, Ghofrani H, Torbicki A, Barst RJ, Rubin LJ, Badesch D et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353(20): 2148-57.

  37. Michelakis E, Tymchack W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: Comparison with inhaled nitric oxide. Circulation 2002; 105: 2398-403.




2020     |     www.medigraphic.com